Refractory Primary Peritoneal Carcinoma: Clinical Trials

4 trials for Refractory Primary Peritoneal Carcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 recruiting, 1 terminated. 4 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Completed 2, Recruiting 1, Terminated 1
Phase 11Terminated 1

Follow Refractory Primary Peritoneal Carcinoma: new trials by email Literature Review of Refractory Primary Peritoneal Carcinoma trials Research Report on Refractory Primary Peritoneal Carcinoma

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Bevacizumab, Irinotecan Sucrosofate - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Phase 2CompletedNorthwestern University32021-03-162023-01-19
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
Akt/ERK Inhibitor ONC201, Paclitaxel, Questionnaire Administration - Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma
Phase 2RecruitingIra Winer622020-01-212026-06-17
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Batiraxcept, Durvalumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center122019-12-032025-06-11
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Durvalumab, Tremelimumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Phase 2CompletedM.D. Anderson Cancer Center1002017-05-182026-08-05

Narrower conditions

Fallopian Tube Neoplasms (4)  ·  Ovarian Neoplasms (4)

Broader conditions

Adnexal Diseases (4)  ·  Endocrine Gland Neoplasms (4)  ·  Endocrine System Diseases (4)  ·  Fallopian Tube Diseases (4)  ·  Female Urogenital Diseases (4)  ·  Female Urogenital Diseases and Pregnancy Complications (4)  ·  Genital Diseases (4)  ·  Genital Diseases, Female (4)  ·  Genital Neoplasms, Female (4)  ·  Gonadal Disorders (4)  ·  Neoplasms (4)  ·  Neoplasms by Site (4)  ·  Ovarian Diseases (4)  ·  Urogenital Diseases (4)  ·  Urogenital Neoplasms (4)

Interventions

Disulfides (3)  ·  Immunoglobulin G (3)  ·  durvalumab (2)  ·  AVB-500 fusion protein (1)  ·  Bevacizumab (1)  ·  Esters (1)  ·  Paclitaxel (1)  ·  TIC10 compound (1)  ·  Taxes (1)  ·  irinotecan sucrosofate (1)  ·  tremelimumab (1)

Sponsors

M.D. Anderson Cancer Center (2)  ·  Ira Winer (1)  ·  Northwestern University (1)

Countries

United States (4)

Top investigators

Amir A Jazaeri (2)  ·  Daniela E Matei, M.D. (1)  ·  Ira Winer, M.D. (1)

Results publications

PMID 38009662

NIH funding

P30CA060553 (1)